You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

462 Results
Guidelines and Advice
Status: In-Review
ID: 6-13
Mar 2018
Document
Jun 2018
Document
Jun 2018
Guidelines and Advice
Status: Current
Version: 1
Jun 2018
Drug
Other Name(s): Alunbrig®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jul 2024
Guidelines and Advice
Status: Current
ID: N/A
Version: 1
Nov 2018
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brigatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
bevacizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Blog posts

Blog Category: Our Partners and the System

Recently, I provided opening remarks at an event that brought together various stakeholders to discuss opportunities and challenges presented by the...
Dec 2018
Document
Dec 2018
Blog posts

Blog Category: Insights & Perspectives

This past spring I was giving a talk about the My CancerIQ risk assessment tool at one of Ontario’s largest primary care conferences. And, as I so...
Jan 2019

Pages